Founded in 2018, EMBA is a privately-held, early commercial stage developer of the HourGlass® integrated vascular occlusion/embolization system. FDA cleared and CE Marked, the HourGlass® is a highly differentiated, ?Best in Class? implant delivered over-the-wire (?OTW?) to occlude/embolize arterial and venous vessels between 3-8mm. The total addressable market (?TAM?) for the 5F HourGlass® platform is estimated to exceed $300 million globally. An expected US label expansion to 3-8mm for arterial and 6-8mm for venous offers additional versatility as will a 3F product currently in development.